{"entity":{"id":"plcg2","kind":"target","name":"PLCG2","aka":["phospholipase C gamma 2","1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2"],"tldr":"PLCG2 (1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Chronic lymphocytic leukaemia.","summary":"The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes. It is a crucial enzyme in transmembrane signalling.\n\nCIViC holds 3 clinical evidence items and 0 assertions across 3 variants, naming Venetoclax.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:9066","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9066"},{"label":"UniProt P16885","url":"https://www.uniprot.org/uniprotkb/P16885/entry"},{"label":"NCBI Gene 5336","url":"https://www.ncbi.nlm.nih.gov/gene/5336"},{"label":"Ensembl ENSG00000197943","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197943"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["cll"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 3 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"PLCG2","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:9066","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9066","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P16885","url":"https://www.uniprot.org/uniprotkb/P16885/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene PLCG2","url":"https://civicdb.org/features/4327","note":"3 evidence items, 0 assertions, 3 variants; diseases: Chronic Lymphocytic Leukaemia (GraphQL API, CC0)"}],"hgnc":"HGNC:9066","ensembl":"ENSG00000197943","uniprot":"P16885","entrez":"5336","biology":"The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes. It is a crucial enzyme in transmembrane signalling. Location: Membrane raft (UniProt). Locus 16q24.1 (HGNC).","whereFound":["Chronic lymphocytic leukaemia: CIViC evidence names this disease"],"targetClass":"enzyme","prevalence":[]},"route":"/targets/plcg2/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}]}}